MTVAMetaVia Inc. Common Stock
1.460USD-0.68%Mkt Cap: 9.62M $P/E: —3d ago
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with devel…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap9.62M $
Enterprise Value-2.97M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-12.97M $
Revenue/Share—
Last Price1.460 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA0.20
EV/Revenue—
P/S—
P/B1.39
EPS (TTM)-2.41
EPS (Forward)—
52W Range
0.96603% of range19.03
52W High19.03 USD
52W Low0.9660 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-243.26%
ROA-116.63%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.70M $
CapEx (TTM)2.00K $
FCF Margin—
FCF Yield-115.26%
Net Debt-12.46M $
Net Debt/EBITDA0.84
Balance Sheet
Debt/Equity0.04
Current Ratio2.06
Quick Ratio1.99
Book Value/Sh1.037 USD
Cash/Share1.918 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 31, 2019
Splits
Last Split1:11
Split DateDec 5, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)19.33 USD
Upside (mean)+1224.2%
Target Range8.000 USD – 30.00 USD
$8.000+1224.2% to mean$30.00
# Analysts3
Ownership
Shares Out.6.59M
Float4.81M
Insiders28.61%
Institutions13.87%
Short Interest
Short Ratio0.3d
Short % Float4.74%
Short % Out.3.11%
Shares Short160.46K
Short (prev mo.)124.04K
Technical
SMA 501.577 (-7.4%)
SMA 2003.446 (-57.6%)
Beta0.90
S&P 52W Chg18.16%
Avg Vol (30d)395.06K
Avg Vol (10d)92.09K
Technical Indicators
RSI (14)43.8
MACD-0.0484
MACD Signal-0.0616
MACD Hist.+0.0132
BB Upper1.512 USD
BB Middle1.461 USD
BB Lower1.410 USD
BB Width7.04%
ATR (14)0.1042 USD
Vol Ratio (20d)0.54x